Intercytex Group

Intercytex Group is a biotechnology company developing cell-based therapies for the repair and regeneration of skin and hair.

Intercytex Group plc, a development stage biotechnology company, engages in the research, development, and commercialization of cell-based therapies for the repair and regeneration of skin and hair. The company, using its integrated cell technology platform, develops living, human cell-based products. Its product programs in development include VAVELTA, a facial rejuvenation and skin damage repair product, which completed Phase II trials; SHEF-1-Stem Cell Line, which would develop a cure for AMD, the leading cause of blindness in the elderly; ICX-TRC, a hair regeneration product that completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which completed Phase I trial. The company was founded in 2000 and is headquartered in Cambridge, the United Kingdom.